June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a ...

OST-HER2 has received Rare Pediatric Disease Designation for osteosarcoma from the FDA. If it receives a conditional BLA via Accelerated Review before September 30, 2026, it will become eligible for a ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...